A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to investigate the objective response rate in patients receiving
GEMOX (gemcitabine plus oxaliplatin) plus cetuximab as first line treatment in advanced or
metastatic unresectable BTC biliary tract cancer compared to patients receiving the same
chemotherapy without cetuximab. The secondary objectives include the exploration of the
effect of the multimodality strategy on progression-free and overall survival, biomarker
prediction, and toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Kaohsiung Medical University Kaohsiung Veterans General Hospital. Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taichung Veterans General Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital